The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Catecholamine
Guideline
Neuroblastoma
PET-CT
Paediatric PET
[124I]MIBG, 18F-MFBG, 11C-HED
[18F]F-DOPA
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
received:
13
07
2023
accepted:
21
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
aheadofprint
Résumé
Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ We searched the PubMed database for studies performing a head-to-head comparison between [ Ten studies were selected: two regarding [ PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination.
Sections du résumé
BACKGROUND
BACKGROUND
Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [
METHODS
METHODS
We searched the PubMed database for studies performing a head-to-head comparison between [
RESULTS
RESULTS
Ten studies were selected: two regarding [
CONCLUSIONS
CONCLUSIONS
PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination.
Identifiants
pubmed: 37962616
doi: 10.1007/s00259-023-06486-9
pii: 10.1007/s00259-023-06486-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21. https://doi.org/10.1186/1471-2407-11-21 .
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015 20;33:3008–17. https://doi.org/10.1200/JCO.2014.59.4648 .
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children’s oncology group study. J Clin Oncol. 2009;27:1007–13. https://doi.org/10.1200/JCO.2007.13.8925 .
Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24. https://doi.org/10.1007/s00259-018-4070-8 .
Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305. https://doi.org/10.1007/s00259-017-3829-7 .
Boubaker A, Poetschger U, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, et al. Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials. J Clin Oncol. 2014;32. https://doi.org/10.1200/jco.2014.32.15_suppl.10029 .
Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59:502–8.
doi: 10.2967/jnumed.117.195883
pmcid: 5868501
Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35:153–5. https://doi.org/10.1002/1096-911x(200008)35:23.0.co;2-7 .
Bleeker G, Tytgat GAM, Adam JA, Caron HN, Kremer LCM, Hooft L, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 29;2015:CD009263. https://doi.org/10.1002/14651858.CD009263.pub2 .
Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by 123 I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26. https://doi.org/10.1038/sj.bjc.660562 .
Mcinnes MDF, Moher D, Thombs BD, Mcgrath TA, Bossuyt PM. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies the PRISMA-DTA statement supplemental content CME Quiz at jamanetwork.com/learning. JAMA. 2018;319:388–96. https://doi.org/10.1001/jama.2017.19163 .
Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009 .
Piccardo A, Morana G, Puntoni M, Campora S, Sorrentino S, Zucchetta P, et al. Diagnosis, treatment response, and prognosis: The role of
Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21.
Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-Body PET/CT with11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635-42
Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of
Hemrom A, Arora G, Damle NA, Bal C. Comparative role of 18F-DOPA PET/CT and 131I-MIBG scintigraphy in neuroblastoma and application of curie and SIOPEN scoring systems in 18F-DOPA PET/CT. Nucl Med Mol Imaging. 2022;56:236–44. https://doi.org/10.1007/s13139-022-00762-6 .
Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, et al. 124I-MIBG PET/CT to monitor metastatic disease in children with relapsed neuroblastoma. J Nucl Med. 2021;62(1):43–7. https://doi.org/10.2967/jnumed.120.243139 .
Samim A, Blom T, Poot AJ, Windhorst AD, Fiocco M, Tolboom N, et al. Correction to: [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50(4):1146–57. https://doi.org/10.1007/s00259-022-06063-6 .
doi: 10.1007/s00259-022-06063-6
pubmed: 36504277
Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54:42–9. https://doi.org/10.2967/jnumed.112.102772 .
Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097–106. https://doi.org/10.1007/s00259-023-06221-4 .
Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and Dosimetry of
doi: 10.2967/jnumed.117.193169
pubmed: 28705916
pmcid: 5750519
Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, et al.
Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57. https://doi.org/10.1053/j.semnuclmed.2016.10.007 .
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–43. https://doi.org/10.2967/jnumed.108.060467 .
Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343–9. https://doi.org/10.1200/JCO.2008.20.5732 .
Telli T, Lay Ergün E, Volkan Salanci B, Özgen Kiratli P. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45:326–9. https://doi.org/10.1097/RLU.0000000000002961 .
Pandit-Taskar N, Modak S. Norepinephrine transporter as a target for imaging and therapy. J Nucl Med. 2017;58:39S–53S. https://doi.org/10.2967/jnumed.116.186833 .
Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8. https://doi.org/10.1097/RLU.0000000000001984 .
Černý I, Prášek J, Kašpárková H. Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 20165;55:151–7. https://doi.org/10.3413/Nukmed-0743-15-0 .
Borgwardt L, Brok JS, Andersen KF, Madsen J, Gillings N, Fosbøl M, et al. [18F]mFBG long axial field of view PET-CT without general anaesthesia reveals concise extension of neuroblastoma in a 9-month-old boy. Eur J Nucl Med Mol Imaging. 2023;50:2563–64. https://doi.org/10.1007/s00259-023-06160-0 .
Fiz F, Bini F, Gabriele E, Bottoni G, Garrè M, Marinozzi F, Milanaccio C, Verrico A, Massollo M, Bosio V, Lattuada M, Rossi APA. Role of dynamic parameters of 18F-DOPA PET/CT in pediatric gliomas. Clin Nucl Med. 2022;47:517–24.
doi: 10.1097/RLU.0000000000004185
pubmed: 35353725
Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3:8.
doi: 10.1186/s40658-016-0144-5
pmcid: 4894854
Beijst C, de Keizer B, Lam MGEH, Janssens GO, Tytgat GAM, de Jong HWAM. A phantom study: Should124I-mIBG PET/CT replace123I-mIBG SPECT/CT? Med Phys. 2017;44:1624–31. https://doi.org/10.1002/mp.12202 .
Braghirolli AMS, Waissmann W, Da Silva JB, Dos Santos GR. Production of iodine-124 and its applications in nuclear medicine. Appl Radiat Isot. 2014;90:138–48. https://doi.org/10.1016/j.apradiso.2014.03.026 .
Piccardo A, Lopci E, Conte M, Cabria M, Cistaro A, Garaventa A, et al. Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan. Clin Nucl Med. 2014;39:e80–3. https://doi.org/10.1097/RLU.0b013e31827a0002 .
Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and dosimetry of 18 F-meta-fluorobenzylguanidine: A first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59:147-153. https://doi.org/10.2967/jnumed.117.193169 .
Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: Current status and new developments. J Pers Med. 2021;11:270. https://doi.org/10.3390/jpm11040270 .